



## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: <https://www.ebnl.org>

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

EBN/2020/S-LDF21

August 10, 2020

DCS - CRD

The BSE Ltd

25<sup>th</sup> floor, Phiroze Jeejeebhoy Towers

Dalal Street, Fort, Mumbai – 400 001,

Sub: Disclosure of material impact of COVID-19 pandemic on the company under SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

Ref: Scrip Code No. 524768

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, the disclosure of material impact of CoVID-19 pandemic on the Company is enclosed herewith as Annexure.

Kindly take the same in your record.

Thanking you,

Yours faithfully,

For Emmessar Biotech & Nutrition Ltd

 

Compliance Officer

Encl: As above.



## **EMMESSAR BIOTECH & NUTRITION LTD**

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: <https://www.ebnl.org>

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

### **ANNEXURE**

#### **1. Impact of the COVID-19 pandemic on the business:**

Government has imposed lockdown from 22nd March 2020 due to outbreak of Coronavirus Disease (CoVID-19) a global pandemic. As reported by management CoVID-19 badly affected the Company and the Company is yet to start its regular business activity. The Management has considered the global economic conditions prevailing and has used internal and external sources of information to the extent determined by it. The actual outcome of these assumptions and estimates may vary in future due to the impact of pandemic. The Company will continue to closely monitor any material changes to future economic conditions.

#### **2. Ability to maintain operations including the factories / manufacturing units / office.**

The office and the manufacturing unit are working partially as per Government guidelines, and have despatched one export consignment. Only one personnel is attending the office and rest are working from home.

#### **3. Schedule., if any, for restarting the operations:**

As reported by management CoVID-19 badly affected the Company and the Company is yet to start its regular business/manufacturing activity.

#### **4. Steps taken to ensure smooth functioning of operations:**

Covid-19 pandemic does have major effect on the business of the Company. After lockdown company's office and manufacturing units were completely shut down, as per directions of Government. The office is still closed, those who joined the Company are doing working from home based on the guidelines and only one official is attending the office for handling emergency work.

#### **5. Estimation of the future impact of CoVID-19 on its operations:**

It is very early to assess the future impact of COVID-19 with reasonable certainty; however, with the opening of domestic market post lockdown, we expect business to improve gradually.



..... 2





## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: <https://www.ebnl.org>

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

: 2 :

### 6. Details of impact of CoVID-19 On listed entity:

#### i. Capital and financial resources:

We don't have adequate capital to meet business requirements,

#### ii. Profitability:

Profitability for the 1st Quarter of F.Y. 2020-21 have been affected due to lockdown. However, it is expected to improve from 2nd Quarter onwards.

#### iii. Liquidity position:

Liquidity position is very tight in the company.

#### iv. Assets:

The Company sees immediate impairment requirement for assets due to Covid-19.

#### v. Internal financial reporting and control:

Internal financial reporting and control are in place.

#### vi. Supply Chain:

We have observed supply chain issues and it is expected to normalise post lockdown.

#### vii. Demand for its products/ services:

Demand expected to improve post lockdown.

### 7. Existing contracts / agreements where non-fulfilment of the obligations by any party will have significant impact on the listed entity's business:

We have such contract which has significant impact on the company.

